FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose...

U.S. federal officials have approved a new pain pill aimed at preventing addiction and overdose risks linked to opioids like Vicodin and OxyContin....

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

FDA approves Journavx (suzetrigine), a new opioid designed to reduce addiction and overdose risks.

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.